Literature DB >> 11112140

The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis.

A G Nicholson1, T V Colby, R M du Bois, D M Hansell, A U Wells.   

Abstract

Lone cryptogenic fibrosing alveolitis (CFA) is a progressive interstitial lung disease, with a median survival of 3 to 6 yr from the onset of dyspnea. CFA can be subdivided into prognostically significant histopathologic patterns, including nonspecific interstitial pneumonia (NSIP). We reviewed 78 patients with a clinicopathologic diagnosis of CFA, biopsied between 1978 and 1989, to evaluate the prevalence and prognostic significance of these histopathologic patterns, in particular NSIP. Biopsy appearances were reclassified by two pulmonary histopathologists as usual interstitial pneumonia (UIP) (47%), NSIP (36%), or desquamative interstitial pneumonia (DIP)/respiratory bronchiolitis-associated interstitial lung disease (RBILD) (17%). The kappa coefficient of agreement between pathologists was 0.49. In 67 cases, follow-up was complete to death or 10 yr after biopsy, with 50 deaths during a median follow-up of 42 mo (UIP, 89%; NSIP, 61%, DIP/RBILD, 0%). Survival was highest in DIP/RBILD and higher in NSIP than UIP, p < 0.0005. When analysis was confined to patients with UIP or NSIP, the mortality of UIP remained higher, p < 0.01, but the 5-yr survival in patients with fibrotic NSIP was only 45%, indicating that this histologic appearance is often associated with a poor outcome. A response to treatment was more frequent in DIP/RBILD than in NSIP (p < 0.01) or UIP (p < 0.0005). This study confirms the prognostic value of subclassifying patients with CFA according to histopathologic pattern. However, in patients with clinically typical CFA, a histologic diagnosis of fibrotic NSIP needs to be interpreted with caution and does not necessarily denote a good outcome.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11112140     DOI: 10.1164/ajrccm.162.6.2003049

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  101 in total

1.  [Pulmonary fibrosis. Classification, diagnosis, therapy].

Authors:  U Costabel; J Guzman
Journal:  Internist (Berl)       Date:  2003-06       Impact factor: 0.743

Review 2.  Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches.

Authors:  Moisés Selman; Victor J Thannickal; Annie Pardo; David A Zisman; Fernando J Martinez; Joseph P Lynch
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 3.  Idiopathic pulmonary fibrosis-an epidemiological and pathological review.

Authors:  Andrea T Borchers; Christopher Chang; Carl L Keen; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2011-04       Impact factor: 8.667

4.  Focal interstitial CC chemokine receptor 7 (CCR7) expression in idiopathic interstitial pneumonia.

Authors:  E S Choi; E M Pierce; C Jakubzick; K J Carpenter; S L Kunkel; H Evanoff; F J Martinez; K R Flaherty; B B Moore; G B Toews; T V Colby; E A Kazerooni; B H Gross; W D Travis; C M Hogaboam
Journal:  J Clin Pathol       Date:  2006-01       Impact factor: 3.411

5.  Non-specific interstitial pneumonia; as the first clinical presentation of various collagen vascular disorders.

Authors:  Toshio Sato; Jiro Fujita; Ichiro Yamadori; Yuji Ohtsuki; Takeo Yoshinouchi; Shuji Bandoh; Michiaki Tokuda; Toshihiko Ishida
Journal:  Rheumatol Int       Date:  2005-11-08       Impact factor: 2.631

6.  What is this thing called CFA?

Authors:  A U Wells; D M Hansell; A G Nicholson
Journal:  Thorax       Date:  2007-01       Impact factor: 9.139

Review 7.  [Idiopathic interstitial pneumonias: from classification to diagnostic work-up].

Authors:  C Müller-Mang; L Stiebellehner; K Schmid; A Bankier
Journal:  Radiologe       Date:  2007-05       Impact factor: 0.635

Review 8.  Idiopathic pulmonary fibrosis : new concepts in pathogenesis and implications for drug therapy.

Authors:  Jeffrey C Horowitz; Victor J Thannickal
Journal:  Treat Respir Med       Date:  2006

9.  Using hyperpolarized 129Xe MRI to quantify regional gas transfer in idiopathic pulmonary fibrosis.

Authors:  Jennifer M Wang; Scott H Robertson; Ziyi Wang; Mu He; Rohan S Virgincar; Geoffry M Schrank; Rose Marie Smigla; Thomas G O'Riordan; John Sundy; Lukas Ebner; Craig R Rackley; Page McAdams; Bastiaan Driehuys
Journal:  Thorax       Date:  2017-08-31       Impact factor: 9.139

Review 10.  Interstitial lung disease in systemic sclerosis.

Authors:  Predrag Ostojic; Marco Matucci Cerinic; Richard Silver; Kristin Highland; Nemanja Damjanov
Journal:  Lung       Date:  2007 Jul-Aug       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.